AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.245

0.000

Volume:- -

Turnover:- -

Market Cap:148.68M

PE:-1.61

High:0.245

Open:0.245

Low:0.245

Close:0.245

52wk High:0.470

52wk Low:0.135

Shares:606.85M

Float Shares:353.07M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.152

EPS(LYR):-0.152

ROE:-456.96%

ROA:-138.75%

PB:42.84

PE(LYR):-1.61

Loading ...

Overview Company News Filings

Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration

Paradigm Biopharmaceuticals Ltd-Board Initiates Voluntary Administration

THOMSON REUTERS

Paradigm Biopharmaceuticals - Board Intends to Develop Proposal for Deed of Company Arrangement

THOMSON REUTERS

Paradigm Biopharmaceuticals - Clinical Review and Restructuring Process Expected to Take at Least Eight Weeks

THOMSON REUTERS

Paradigm Biopharmaceuticals - Securities Remain Suspended from Trading on ASX During Administration

THOMSON REUTERS

Paradigm Biopharmaceuticals to Return $2 Million of Funds to Obsidian Global

MT Newswires Live

Paradigm Biopharmaceuticals Ltd-Agreement to Return US$2M to Obsidian

THOMSON REUTERS

Paradigm Biopharmaceuticals - 2 Mln Convertible Notes Issued in Tranche 4 Drawdown to be Cancelled

THOMSON REUTERS

Paradigm Biopharmaceuticals' Knee Osteoarthritis Study Fails to Reach Continuation Threshold

MT Newswires Live

Paradigm Biopharmaceuticals Seeks Trading Halt

Paradigm Biopharmaceuticals - Trading Halt Pending Interim Analysis Results for Phase 3 Clinical Trial

THOMSON REUTERS

Paradigm Biopharmaceuticals Names Chief Medical Officer

MT Newswires Live

Paradigm Biopharmaceuticals Ltd-DR Daniel Furtner Appointed Chief Medical Officer

THOMSON REUTERS

Paradigm Biopharmaceuticals Draws Down Final $2 Million of Tranche 4 From Convertible Note Facility; Shares Down 13%

MT Newswires Live

PAR Technology Launches Platform to Connect Restaurant Guest Data

MT Newswires Live

Paradigm Biopharmaceuticals - FY Net Loss Attributable A$56.3 Mln

THOMSON REUTERS

Paradigm Biopharmaceuticals' Phase 3 Knee Osteoarthritis Trial to Continue Unchanged Following Safety Board Recommendation

MT Newswires Live

Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook

Simply Wall St.

Exploring 3 Undervalued Small Caps With Insider Buying Across Regions

Simply Wall St.

Paradigm Biopharmaceuticals Completes Drawdown of $3 Million Tranche Under Convertible Note Facility

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/PAR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.245,"timestamp":1790812891912,"preClose":0.245,"halted":3,"volume":0,"delay":0,"changeRate":0,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":606848701,"eps":-0.152232,"marketStatus":"Halted","change":0,"latestTime":"10-01 10:01:31 AEST","open":0.245,"high":0.245,"low":0.245,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.152232,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790834400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.245,"openAndCloseTimeList":[[1790812800000,1790834400000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PAR.AU","preClose":0.245,"auctionPrice":0.255,"auctionVolume":69,"auction":1,"marketStatus":"盘前竞价","timestamp":1790118118758}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-138.75%","roe":"-456.96%","lyrEps":-0.152232,"shares":606848701,"dividePrice":0,"high":0.245,"amplitude":0,"preClose":0.245,"low":0.245,"week52Low":0.135,"pbRate":"42.84","psRate":"17595.02","week52High":0.47,"institutionHeld":0,"latestPrice":0.245,"eps":-0.152232,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.152232,"open":0.245,"prevYearClose":0.34,"prevWeekClose":0.245,"prevMonthClose":0.245,"prevQuarterClose":0.245,"fiveDayClose":0.245,"twentyDayClose":0.24,"sixtyDayClose":0.17,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671223116","title":"Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2671223116","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671223116?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:52","pubTimestamp":1790725977,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Says Board Initiates Voluntary AdministrationSept 30 (Reuters)-Paradigm Biopharmaceuticals LtdPAR.AX:INITIATES VOLUNTARY ADMINISTRATION PROCESSBOARD INTENDS TO DEVELO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration","news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671997223","title":"Paradigm Biopharmaceuticals Ltd-Board Initiates Voluntary Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2671997223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671997223?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:47","pubTimestamp":1790725675,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671722391","title":"Paradigm Biopharmaceuticals - Board Intends to Develop Proposal for Deed of Company Arrangement","url":"https://stock-news.laohu8.com/highlight/detail?id=2671722391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671722391?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:47","pubTimestamp":1790725675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671322394","title":"Paradigm Biopharmaceuticals - Clinical Review and Restructuring Process Expected to Take at Least Eight Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2671322394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671322394?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:47","pubTimestamp":1790725675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671223910","title":"Paradigm Biopharmaceuticals - Securities Remain Suspended from Trading on ASX During Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2671223910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671223910?lang=en_us&edition=fundamental","pubTime":"2026-09-30 07:47","pubTimestamp":1790725675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUE6WRYYG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669541554","title":"Paradigm Biopharmaceuticals to Return $2 Million of Funds to Obsidian Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2669541554","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669541554?lang=en_us&edition=fundamental","pubTime":"2026-09-24 14:12","pubTimestamp":1790230359,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  agreed to return the $2 million of funds it recently received from Obsidian Global under a fourth-tranche drawdown of its convertible note facility, according to a Thursday filing with the Australian bourse.The 2 million convertible notes issued in connection with the drawdown will be cancelled, and no premium, redemption amount, or other amount is payable by Paradigm under the arrangement, per the filing.The development follows the interim efficacy result for Paradigm's phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis failing to reach the threshold required for the study to proceed.The company is reviewing data to better understand what impact that trial result will have on its financial position and future operations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451310","title":"Paradigm Biopharmaceuticals Ltd-Agreement to Return US$2M to Obsidian","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669451310?lang=en_us&edition=fundamental","pubTime":"2026-09-24 13:25","pubTimestamp":1790227524,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUE2K4JSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669341451","title":"Paradigm Biopharmaceuticals - 2 Mln Convertible Notes Issued in Tranche 4 Drawdown to be Cancelled","url":"https://stock-news.laohu8.com/highlight/detail?id=2669341451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669341451?lang=en_us&edition=fundamental","pubTime":"2026-09-24 13:25","pubTimestamp":1790227524,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUE2K4JSC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669170131","title":"Paradigm Biopharmaceuticals' Knee Osteoarthritis Study Fails to Reach Continuation Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=2669170131","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669170131?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:03","pubTimestamp":1790143392,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said the interim efficacy result for its phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis did not reach the threshold required for the study to proceed, according to a Wednesday filing with the Australian bourse.Operational challenges resulted in a \"significant amount of missing data\" that impacted the interim analysis, which was conducted after about 50% of participants reached the day 112 primary efficacy endpoint, the company said.Paradigm is reviewing the available data to better understand the extent of the impact. It expects to disclose the financial and funding implications of the outcome by Sept. 28.The company said it is assessing the implications for its financial position and future operations, including a review of potential trial wind-down costs. It added that \"material uncertainty\" remains over the consequences of the trial outcome and the company's path forward.Paradigm shares will remain suspen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669135172","title":"Paradigm Biopharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2669135172","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669135172?lang=en_us&edition=fundamental","pubTime":"2026-09-21 09:10","pubTimestamp":1789953056,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Seeks Trading HaltSept 21 (Reuters)-Paradigm Biopharmaceuticals LtdPAR.AX:TRADING HALT PENDING INTERIM ANALYSIS RESULTS FOR PHASE 3 CLINICAL TRIALFurther company coverage:PAR.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45B00N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669764180","title":"Paradigm Biopharmaceuticals - Trading Halt Pending Interim Analysis Results for Phase 3 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669764180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669764180?lang=en_us&edition=fundamental","pubTime":"2026-09-21 06:48","pubTimestamp":1789944490,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nFWN45B00N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667947016","title":"Paradigm Biopharmaceuticals Names Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667947016","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667947016?lang=en_us&edition=fundamental","pubTime":"2026-09-15 08:39","pubTimestamp":1789432751,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  appointed Daniel Furtner as its Chief Medical Officer, effective Wednesday, according to a Tuesday Australian bourse filing.Furtner succeeds Donna Skerrett, who will remain with the firm as a senior scientific advisor.Furtner previously served as the senior director of medical affairs for the Asia Pacific region at CSL.Its shares fell 2% in recent trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667911446","title":"Paradigm Biopharmaceuticals Ltd-DR Daniel Furtner Appointed Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667911446","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667911446?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:47","pubTimestamp":1789429621,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUE69ZBXD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666954810","title":"Paradigm Biopharmaceuticals Draws Down Final $2 Million of Tranche 4 From Convertible Note Facility; Shares Down 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666954810","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666954810?lang=en_us&edition=fundamental","pubTime":"2026-09-11 11:50","pubTimestamp":1789098623,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  drew down the remaining balance of tranche 4, valued at $2 million, under its $27 million convertible note facility with Obsidian Global Partners, according to a Friday Australian bourse filing.Following the drawdown, about $5 million remains available under the facility, providing continued financial flexibility to support phase 3 execution and broader commercial readiness activities, the filing added.The company's shares plunged 13% in recent Friday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PAR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664548468","title":"PAR Technology Launches Platform to Connect Restaurant Guest Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2664548468","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664548468?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:17","pubTimestamp":1788268623,"startTime":"0","endTime":"0","summary":"PAR Technology  said Tuesday it has launched a new customer data platform to recognize restaurant guests from their first transaction and unify activity across ordering, payment and other channels.The Guest360 platform works alongside PAR Punchh to create unified guest profiles from in-store, digital and loyalty activity, PAR Technology said.The platform can use the profiles to create dynamic audiences that update automatically based on real spend, visit frequency, menu preference for personalized offers and loyalty milestones, it said.PAR Technology shares were 2% lower in Tuesday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QSR","PAR.AU","BK4157","BK4209","BK7067","PAR","BK4023","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662911058","title":"Paradigm Biopharmaceuticals - FY Net Loss Attributable A$56.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662911058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662911058?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:49","pubTimestamp":1787885347,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659184174","title":"Paradigm Biopharmaceuticals' Phase 3 Knee Osteoarthritis Trial to Continue Unchanged Following Safety Board Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2659184174","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659184174?lang=en_us&edition=fundamental","pubTime":"2026-08-13 09:25","pubTimestamp":1786584355,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said an independent Data Safety Monitoring Board recommended that the company's phase 3 clinical trial of a knee osteoarthritis treatment continue without modification, according to a Thursday filing with the Australian bourse.The trial is evaluating injectable pentosan polysulfate sodium in participants with knee osteoarthritis, with the change in pain intensity at day 112 set as the primary endpoint.The safety board issued the recommendation after completing a review of about 80% of the participants who have completed dosing, the company said.The trial's interim analysis remains on track for September.Paradigm Biopharmaceuticals shares gained 1% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651906","title":"Paradigm Biopharmaceuticals Limited's (ASX:PAR) Profit Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651906","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651906?lang=en_us&edition=fundamental","pubTime":"2026-08-05 12:36","pubTimestamp":1785904609,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Paradigm...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-limiteds-asxpar-profit-outlook","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-par/paradigm-biopharmaceuticals-shares/news/paradigm-biopharmaceuticals-limiteds-asxpar-profit-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PAR","BK4023","PAR.AU","BK7067","BK7508","BK4157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654464009","title":"Exploring 3 Undervalued Small Caps With Insider Buying Across Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2654464009","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654464009?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:09","pubTimestamp":1785236980,"startTime":"0","endTime":"0","summary":"In the last week, the United States market has been flat, but over the past 12 months, it has experienced a 15% rise with earnings forecasted to grow by 17% annually. In this environment, identifying stocks that are potentially undervalued with insider buying can be a strategic approach for investors looking to capitalize on growth opportunities within small-cap companies.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8131000-choice1-main-header/1585186656975"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/exploring-3-undervalued-small-caps-with-insider-buying-acros-16","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-par/par-technology/news/exploring-3-undervalued-small-caps-with-insider-buying-acros-16","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RF","BK4120","LU1883839398.USD","ONT.AU","ONT","BK7508","BK4585","BK4157","BK4588","LU1880398471.USD","LU1880398554.USD","FRST","PAR","BK4211","PAR.AU","BK7067","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651160090","title":"Paradigm Biopharmaceuticals Completes Drawdown of $3 Million Tranche Under Convertible Note Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2651160090","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651160090?lang=en_us&edition=fundamental","pubTime":"2026-07-13 12:00","pubTimestamp":1783915254,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  completed the drawdown of the fourth tranche, valued at $3 million, under its $27 million convertible note facility with Obsidian Global Partners, according to a Monday Australian bourse filing.The drawdown provides additional working capital to support its global phase three clinical trial, evaluating the use of injectable pentosan polysulfate sodium to treat knee osteoarthritis. It completed participant enrolment into the study, with 538 participants randomized.After the drawdown, around $7 million remains available under the facility.Its shares rose 2% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}